Pergolide (mesylate)

$60$228

Products Details

Product Description

– Pergolide mesylate (Pergolide methanesulfonate), an Ergoline derivative, is a potent and orally active dopamine D1 and D2 receptors agonist. Pergolide mesylate can be used for Parkinson’s disease and hyperprolactinaemia research[1][2].

Web ID

– HY-13720A

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– Neuroscience-Neurodegeneration

Molecular Formula

– C20H30N2O3S2

References

– [1]S Franks, et al. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia. Br Med J (Clin Res Ed). 1983 Apr 9;286(6372):1177-9.|[2]Daniela Uberti, et al. Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2). Eur J Pharmacol. 2002 Jan 2;434(1-2):17-20.|[3]Alin Ciobica, et al. The effects of pergolide on memory and oxidative stress in a rat model of Parkinson’s disease. J Physiol Biochem. 2012 Mar;68(1):59-69.

CAS Number

– 66104-23-2

Molecular Weight

– 410.59

Compound Purity

– 99.92

SMILES

– [H][C@@]1(N(CCC)C[C@H](CSC)C[C@@]12[H])CC3=CNC4=CC=CC2=C43.CS(=O)(O)=O

Clinical Information

– Launched

Research Area

– Neurological Disease

Solubility

– DMSO : ≥ 25 mg/mL

Target

– Dopamine Receptor

Isoform

– D1 Receptor;D2 Receptor

Pathway

– GPCR/G Protein;Neuronal Signaling

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=